Abbott's FreeStyle Libre 2 and 3 are the first and only patient-applied continuous glucose monitoring (CGM) systems to be ...

The US Food and Drug Administration has okayed removal of the contraindication for use during CT and MRI under certain ...

New research presents a solution to a fundamental challenge: ensuring accurate glucose readings from wearable devices. Read more.

A new consensus statement offers “considerations and good practice points” for the use of continuous glucose monitoring ...

According to Verified Market Research, the global market for such devices is projected to reach 37.4 billion by 2028, growing ...

Medical device maker Dexcom beat Wall Street estimates for third-quarter revenue and profit on Thursday, helped by resilient ...

Glucose Monitoring Devices MarketAs the global burden of diabetes continues to grow, the need for accurate and efficient ...

Abbott today announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs*. The U.S. Food and Drug Administration (FDA) ...

Users of the FreeStyle Libre 2 and 3 continuous glucose monitoring systems from Abbott no longer need to remove and discard the devices for imaging procedures, such as X-rays, CT ...

One of my top priorities when taking on the role of CEO last December was to address the pre-existing Nasdaq listing requirement deficiencies. This has now been achieved and we are pleased to have ...

The company offers blood glucose monitoring systems, continuous glucose monitoring systems, and diabetes application; patient and record billing software, including electronic medical record ...

Insulin affordability and availability across Europe are just part of the complex diabetes management dynamics challenging ...